This brand name is authorized in United States
The drug YUPELRI contains one active pharmaceutical ingredient (API):
|
1
Revefenacin
UNII G2AE2VE07O - REVEFENACIN
|
|
Revefenacin is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. It is used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| YUPELRI Inhalation solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: US | FDA, National Drug Code | Identifier(s): 49502-806 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
